CytomX Therapeutics Inc (CTMX)vsRegeneron Pharmaceuticals Inc (REGN)
CTMX
CytomX Therapeutics Inc
$3.29
-1.79%
HEALTHCARE · Cap: $716.89M
REGN
Regeneron Pharmaceuticals Inc
$793.74
+1.57%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 84775% more annual revenue ($15.53B vs $18.30M). REGN leads profitability with a 27.9% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 66/100 (B-).
CTMX
Avoid33
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.1%
Fair Value
$3.14
Current Price
$3.29
$0.15 premium
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$793.74
$610.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 60.6% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -26.4% — below average capital efficiency
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTMX
The strongest argument for CTMX centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : CTMX
The primary concerns for CTMX are Market Cap, Profit Margin, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
CTMX profiles as a value stock while REGN is a growth play — different risk/reward profiles.
CTMX carries more volatility with a beta of 2.14 — expect wider price swings.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 33/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CytomX Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?